Michiko Tawada

Fujisawa, 2518555, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Discovery of Highly Potent Noncovalent Inhibitors of SARS-CoV-2 Main Protease through Computer-Aided Drug Design.

Discovery of Highly Potent Noncovalent Inhibitors of SARS-CoV-2 Main Protease through Computer-Aided Drug Design.

Journal: Journal of medicinal chemistry

Published: October 12, 2025

Repurposing of the RIPK1-Selective Benzo[1,4]oxazepin-4-one Scaffold for the Development of a Type III LIMK1/2 Inhibitor.

Repurposing of the RIPK1-Selective Benzo[1,4]oxazepin-4-one Scaffold for the Development of a Type III LIMK1/2 Inhibitor.

Journal: ACS chemical biology

Published: April 14, 2025

Discovery of a Novel Series of Potent, Selective, Orally Available, and Brain-Penetrable C1s Inhibitors for Modulation of the Complement Pathway.

Discovery of a Novel Series of Potent, Selective, Orally Available, and Brain-Penetrable C1s Inhibitors for Modulation of the Complement Pathway.

Journal: Journal of medicinal chemistry

Published: April 30, 2023

Discovery of a Novel and Brain-Penetrant O-GlcNAcase Inhibitor via Virtual Screening, Structure-Based Analysis, and Rational Lead Optimization.

Discovery of a Novel and Brain-Penetrant O-GlcNAcase Inhibitor via Virtual Screening, Structure-Based Analysis, and Rational Lead Optimization.

Journal: Journal of medicinal chemistry

Published: January 06, 2021

Identification of a selective DDX3X inhibitor with newly developed quantitative high-throughput RNA helicase assays.

Identification of a selective DDX3X inhibitor with newly developed quantitative high-throughput RNA helicase assays.

Journal: Biochemical and biophysical research communications

Published: December 16, 2019

Identification of 2,6-Disubstituted 3H-Imidazo[4,5-b]pyridines as Therapeutic Agents for Dysferlinopathies through Phenotypic Screening on Patient-Derived Induced Pluripotent Stem Cells.

Identification of 2,6-Disubstituted 3H-Imidazo[4,5-b]pyridines as Therapeutic Agents for Dysferlinopathies through Phenotypic Screening on Patient-Derived Induced Pluripotent Stem Cells.

Journal: Journal of medicinal chemistry

Published: September 25, 2019

TP-064, a potent and selective small molecule inhibitor of PRMT4 for multiple myeloma.

TP-064, a potent and selective small molecule inhibitor of PRMT4 for multiple myeloma.

Journal: Oncotarget

Published: November 11, 2017

Discovery of orally efficacious RORγt inverse agonists. Part 2: Design, synthesis, and biological evaluation of novel tetrahydroisoquinoline derivatives.

Discovery of orally efficacious RORγt inverse agonists. Part 2: Design, synthesis, and biological evaluation of novel tetrahydroisoquinoline derivatives.

Journal: Bioorganic & medicinal chemistry

Published: October 11, 2017

Design of potent dipeptidyl peptidase IV (DPP-4) inhibitors by employing a strategy to form a salt bridge with Lys554.

Design of potent dipeptidyl peptidase IV (DPP-4) inhibitors by employing a strategy to form a salt bridge with Lys554.

Journal: Bioorganic & medicinal chemistry letters

Published: February 01, 2017

Discovery of Novel and Potent Stearoyl Coenzyme A Desaturase 1 (SCD1) Inhibitors as Anticancer Agents.

Discovery of Novel and Potent Stearoyl Coenzyme A Desaturase 1 (SCD1) Inhibitors as Anticancer Agents.

Journal: Bioorganic & medicinal chemistry

Published: February 01, 2017

Structure-based design of a new series of N-(piperidin-3-yl)pyrimidine-5-carboxamides as renin inhibitors.

Structure-based design of a new series of N-(piperidin-3-yl)pyrimidine-5-carboxamides as renin inhibitors.

Journal: Bioorganic & medicinal chemistry

Published: August 22, 2016

Novel approach of fragment-based lead discovery applied to renin inhibitors.

Novel approach of fragment-based lead discovery applied to renin inhibitors.

Journal: Bioorganic & medicinal chemistry

Published: August 09, 2016

Showing 1-12 of 19

Last Updated: 09/26/2026